These results suggest that gefitinib could enhance antitumor immunity by improving lung cancer cell recognition and engulfment by immune phagocytes chiefly through CD47 down-regulation, thereby inhibiting tumor cell viability not only through TK-dependent mechanisms but also by enhancing innate anticancer immune responses. This evidence concerns the gene CD47 and lung carcinoma.